The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment. The aim of this study is to detect the expression of PD-1 on advaced osteosarcoma patient who might use these antibodies for treatment. All those specimen should be taken by pathologist and confirmed with high tumor cellularity.
Study Type
OBSERVATIONAL
Enrollment
50
patients will receive anti-PD-1/anti-PD-L1 antibody for further treatment
Musculoskeletal Tumor Center of Peking University People's Hospital
Beijing, Beijing Municipality, China
RECRUITINGPD-L1 expression level
all those specimens will be tested for expression level,Tumors with ≥50% cells showing positive membrane staining were considered to have high expression of PD-L1
Time frame: 2 months
progression free survival
from the timing of testing to disease progression/death whichever comes first
Time frame: 2 years
overall survival
from the timing of testing to death/last follow-up
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.